Efficacy of Gemcitabine Plus Nab-Paclitaxel in Second-Line Treatment of Metastatic Pancreatic Cancer
dc.authorid | Arici, Mustafa Ozgur/0000-0001-9821-6368 | |
dc.authorscopusid | 57215653678 | |
dc.authorscopusid | 57190280701 | |
dc.authorscopusid | 56644431400 | |
dc.authorscopusid | 57191164749 | |
dc.authorscopusid | 57219782123 | |
dc.authorscopusid | 24339272800 | |
dc.authorscopusid | 57217738098 | |
dc.authorwosid | Aydin, İbrahim/Abi-5071-2020 | |
dc.authorwosid | Komuroglu, Ahmet/R-4769-2019 | |
dc.authorwosid | Ergun, Yakup/N-3273-2018 | |
dc.authorwosid | Arici, Mustafa Ozgur/Jfa-7506-2023 | |
dc.authorwosid | Ozcelik, Melike/Aas-7557-2020 | |
dc.authorwosid | Sönmez, Müge/Izq-2195-2023 | |
dc.authorwosid | Erdem, Mehmet/Aan-5283-2021 | |
dc.contributor.author | Sezgin, Y. | |
dc.contributor.author | Karhan, O. | |
dc.contributor.author | Aldemir, M.N. | |
dc.contributor.author | Ürün, M. | |
dc.contributor.author | Erçek, B.M. | |
dc.contributor.author | Urakcı, Z. | |
dc.contributor.author | Ergün, Y. | |
dc.date.accessioned | 2025-05-10T17:29:44Z | |
dc.date.available | 2025-05-10T17:29:44Z | |
dc.date.issued | 2025 | |
dc.department | T.C. Van Yüzüncü Yıl Üniversitesi | en_US |
dc.department-temp | [Sezgin Y.] Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Karhan O.] Department of Medical Oncology, Faculty of Medicine, Harran University, Şanlıurfa, Turkey; [Aldemir M.N.] Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Ürün M.] Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Erçek B.M.] Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Urakcı Z.] Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakır, Turkey; [Arvas H.] Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakır, Turkey; [Tunç S.] Urfa Mehmet Akif Inan Regional Training Research Hospital Oncology Department, Şanlıurfa, Turkey; [Erdem M.] Department of Internal Medicine, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Yerlikaya H.] Diyarbakır private Batı Hospital Medical Oncology Department, Diyarbakır, Turkey; [İleri S.] Gazi Yaşargil Regional Training Research Hospital Oncology Department, Diyarbakır, Turkey; [Aydın İ.] Department of Internal Medicine, Van Regional Training Research Hospital, Van, Turkey; [Bicer A.] Department of Internal Medicine, Van Regional Training Research Hospital, Van, Turkey; [Kömüroğlu A.U.] Health Service Vocational School of Higher Education, Van Yüzüncü Yıl University, Van, Turkey; [Majidova N.] Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey; [Gökçek S.] Department of Medical Oncology, Faculty of Medicine, Eyül University, İzmir, Turkey; [Demir H.] Department of Medical Oncology, Faculty of Medicine, Afyon Karahisar University, Afyonkarahisar, Turkey; [Yıldız S.] Department of Medical Oncology, Faculty of Medicine, Afyon Karahisar University, Afyonkarahisar, Turkey; [Akbaş S.] Department of Medical Oncology, Faculty of Medicine, Koç University, Istanbul, Turkey; [Özen E.] Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey; [Kahya B.U.] Department of Medical Oncology, Faculty of Medicine, Gazi University, Ankara, Turkey; [sali M.] Department of Medical Oncology, Faculty of Medicine, Uludağ University, Bursa, Turkey; [Anık H.] Abdurrahman Yurtaslan Regional Training Research Hospital Oncology Department, Ankara, Turkey; [Aykut T.] Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey; [Araz M.] Department of Medical Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey; [Alkan A.] Department of Medical Oncology, Faculty of Medicine, Muğla Sıtkı Kocaman University, Muğla, Turkey; [Özçelik M.] Ümraniye Regional Training Research Hospital Oncology Department, Istanbul, Turkey; [Sakin A.] İstanbul Private Medicalpark Hospital Medical Oncology Department, Istanbul, Turkey; [Aykan M.B.] Gülhane Regional Training Research Hospital Oncology Department, Ankara, Turkey; [Mehtıyev M.] Department of Medical Oncology, Bilkent City Hospital, Ankara, Turkey; [Demir B.] Faculty of Medicine, Department of Medical Oncology, Adana Menderes University, Aydın, Turkey; [Başer M.N.] Faculty of Medicine, Department of Medical Oncology, Adana Menderes University, Aydın, Turkey; [Sönmez M.] Department of Medical Oncology, Faculty of Medicine, Department of Medical Oncology, Ordu State Hospital, Sanko University, 26 İstanbul Regional, Istanbul, Turkey; [Gültürk İ.] Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Avcı N.] Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Urvay S.] Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Arıcı M.Ö.] Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Kalender M.E.] Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Yıldırım M.] Department of Medical Oncology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey; [Solmaz A.A.] Department of Medical Oncology, Adana City Hospital, Adana, Turkey; [Gürbüz M.] Department of Medical Oncology, Adana City Hospital, Adana, Turkey; [Ergün Y.] Department of Medical Oncology, Diyarbakır Private Bower Hospital, Diyarbakır, Turkey | en_US |
dc.description.abstract | Despite numerous studies on second-line therapies in metastatic pancreatic cancer, there is no randomized study evaluating the efficacy of gemcitabine plus nab-paclitaxel as a second-line treatment. This study aims to examine the efficacy of gemcitabine plus nab-paclitaxel in second-line therapy. In this retrospective study, a total of 218 patients from 23 centers were included. The primary endpoint was progression-free survival (PFS), secondary endpoints included overall survival (OS), treatment efficacy based on ECOG performance status (PS), and tumor marker (CEA, CA 19 − 9) levels. In the second-line treatment with gemcitabine plus nab-paclitaxel, the median PFS was 5.1 months (95% CI, 5.6 to 7.1), and the median OS was 8.6 months (95% CI, 7.3 to 10.0). Median PFS was 6.6 months in patients with normal CEA levels compared to 4.4 months in patients with high CEA levels (P = 0.01). Median PFS was 6 months in patients with ECOG PS 0–1 compared to 3.8 months in patients with PS 2 (P < 0.01). This study demonstrates the contribution of gemcitabine plus nab-paclitaxel in both OS and PFS in second-line treatment of metastatic pancreatic cancer. It was found to be a good option especially for young patients with good ECOG PS. © The Author(s) 2025. | en_US |
dc.description.woscitationindex | Science Citation Index Expanded | |
dc.identifier.doi | 10.1038/s41598-025-96157-6 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.issue | 1 | en_US |
dc.identifier.pmid | 40188172 | |
dc.identifier.scopus | 2-s2.0-105003097205 | |
dc.identifier.scopusquality | Q1 | |
dc.identifier.uri | https://doi.org/10.1038/s41598-025-96157-6 | |
dc.identifier.volume | 15 | en_US |
dc.identifier.wos | WOS:001460349000023 | |
dc.identifier.wosquality | Q2 | |
dc.language.iso | en | en_US |
dc.publisher | Nature Research | en_US |
dc.relation.ispartof | Scientific Reports | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Gemcitabine Plus Nab-Paclitaxel | en_US |
dc.subject | Metastatic Pancreatic Cancer | en_US |
dc.subject | Overall Survival | en_US |
dc.subject | Progression-Free Survival | en_US |
dc.title | Efficacy of Gemcitabine Plus Nab-Paclitaxel in Second-Line Treatment of Metastatic Pancreatic Cancer | en_US |
dc.type | Article | en_US |